您当前的位置：
首页 >
文章列表页 >
Rapid health technology assessment of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
更新时间：2025-12-10

    • Rapid health technology assessment of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus

    • “The latest research shows that SGLT-2 inhibitors need to be individually selected for the treatment of type 2 diabetes. Enggliptin has the best overall safety and economic advantages.”
    • ZHONGGUO YAOFANG   Vol. 36, Issue 23, Pages: 2978-2984(2025)

    • DOI：10.6039/j.issn.1001-0408.2025.23.17    

      CLC： R977.1+5

    • Received：24 June 2025，

      Revised：2025-11-17，

      Accepted：19 November 2025，

      Published：15 December 2025

    移动端阅览

  • PAN Huimin,WANG Yubo,SHAN Huiting,et al.Rapid health technology assessment of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus[J].ZHONGGUO YAOFANG,2025,36(23):2978-2984. DOI： 10.6039/j.issn.1001-0408.2025.23.17.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Pharmacoeconomic evaluation of dapagliflozin and empagliflozin in the treatment of type 2 diabetic kidney disease
Excavation and Evaluation of ADR Signals of SGLT 2 Inhibitors

Related Author

YANG Xu
ZHAO Yifan
LI Wanting
LIU Yongjun
ZHENG Shufen
ZHONG Shilong

Related Institution

School of International Pharmaceutical Business， China Pharmaceutical University
0